A case of Long QT syndrome type 3 aggravated by beta-blockers and alleviated by mexiletine: the role of epinephrine provocation test.
Long QT syndrome (LQTs) is an uncommon genetic disease causing sudden cardiac death with Torsade de Pointes (TdP). The first line drug treatment has been known to be β-blocker. We encountered a 15-year-old female student with LQTs who had prolonged QTc and multiple episodes of syncope or agonal respiration during sleep. Although her T wave morphology in surface electrocardiography resembled LQTs type 1, her clinical presentation was unusual. During the epinephrine test, TdP was aggravated during β-blocker medication, but alleviated by sodium channel blocker (mexiletine). Therefore, she underwent implantable cardioverter defibrillator implantation.
Department of Cardiology, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Junbeom
J
Park
Sook Kyoung
SK
Kim
Hui-Nam
HN
Pak
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D017147:Defibrillators, Implantable; D003937:Diagnosis, Differential; D003935:Diagnostic Techniques, Cardiovascular; D004837:Epinephrine; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000145:classification / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D008801:Mexiletine / Q000627:therapeutic use*; D010375:Pedigree; D013575:Syncope
D000319:Adrenergic beta-Antagonists; D008801:Mexiletine; D004837:Epinephrine